# A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Source: https://onco.cc/trials/nct05057494/  
OnCo record `nct05057494` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Acalabrutinib, Venetoclax and Obinutuzumab in chronic lymphocytic leukaemia, run by AstraZeneca, active and no longer recruiting.

## Summary

A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma is a phase 3 interventional study registered as NCT05057494 by AstraZeneca, with 607 participants enrolled, started 2022-09-12 and due to reach its primary completion in 2027-07-15. Interventions recorded: Acalabrutinib, Venetoclax and Obinutuzumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05057494
- Phase: 3
- Setting: A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Sponsor: AstraZeneca
- Enrolled: 607

## Sources

- ClinicalTrials.gov NCT05057494: https://clinicaltrials.gov/study/NCT05057494

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/), [Obinutuzumab](https://onco.cc/drugs/obinutuzumab/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct05057494.json